Obstetrics and Gynecology University Department, Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Italy.
Gynecol Endocrinol. 2021 Jul;37(7):646-649. doi: 10.1080/09513590.2021.1903420. Epub 2021 Mar 22.
Estradiol valerate/nomegestrol acetate (E2V/NOMAC) is a new combined oral contraceptive with a good tolerability profile and low drop-out rates, which was shown to improve menstrual-related symptoms. This study aims to evaluate its effectiveness in the control of symptoms and progression of disease in women with ovarian endomestriomas and deep infiltrating endometriosis (DIE).
This was a retrospective cohort study on 39 women with pelvic endometriosis treated with E2V/NOMAC. We assessed for each patient, at the beginning of treatment and after 6 months, the painful symptoms, through a global VAS (Visual Analogue Scale) index and the size of the greatest ovarian and/or deep infiltrating endometriotic lesions.
After 6 months of treatment, a significant reduction was observed for the global VAS score for pain symptoms and for the mean size of ovarian endometriomas, whereas DIE lesions did not present significant changes in mean size.
E2/NOMAC was effective in reducing pain symptoms associated with pelvic endometriosis and the size of ovarian endometriomas, whereas DIE lesions remained stable. This therapy could provide good results in the control of symptoms and disease progression in women with pelvic endometriosis.
戊酸雌二醇/醋酸诺美孕酮（E2V/NOMAC）是一种新的复方口服避孕药，具有良好的耐受性和低脱落率，可改善与月经相关的症状。本研究旨在评估其在控制卵巢子宫内膜异位症和深部浸润性子宫内膜异位症（DIE）患者症状和疾病进展方面的有效性。
这是一项对 39 名接受 E2V/NOMAC 治疗的盆腔子宫内膜异位症女性进行的回顾性队列研究。我们在治疗开始时和 6 个月后评估每位患者的疼痛症状，采用全球 VAS（视觉模拟评分）指数和最大卵巢和/或深部浸润性子宫内膜异位症病变的大小来评估。
治疗 6 个月后，疼痛症状的全球 VAS 评分和卵巢子宫内膜异位症的平均大小均显著降低，而 DIE 病变的平均大小没有显著变化。
E2/NOMAC 可有效减轻与盆腔子宫内膜异位症相关的疼痛症状和卵巢子宫内膜异位症的大小，而 DIE 病变的大小保持稳定。这种治疗方法可能在控制盆腔子宫内膜异位症患者的症状和疾病进展方面提供良好的效果。
